Milan Genge, DO
Ophthalmology · Wilson, NCNPI 1457313363
Payments from drug & device makers
Across 102 payments — averaging $60.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Carl Zeiss Meditec USA, Inc.$4K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$382
- Alcon$353
- Mallinckrodt Hospital Products Inc.$347
- Bausch & Lomb Americas Inc.$166
- AbbVie$151
- plus $654 from 13 others
What the payments were for
- Food & beverage$1,95532%
- Education$982%
- Other$4,15067%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Carl Zeiss Meditec USA, Inc. | 2 | $4,150 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 23 | $382 |
| Alcon | 15 | $353 |
| Mallinckrodt Hospital Products Inc. | 13 | $347 |
| Bausch & Lomb Americas Inc. | 8 | $166 |
| AbbVie(2 entities) | 9 | $151 |
| Oyster Point Pharma, Inc. | 6 | $127 |
| Aerie Pharmaceuticals, Inc. | 9 | $114 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $100 |
| Notal Vision, Inc. | 1 | $64 |
| Kala Pharmaceuticals, Inc. | 2 | $49 |
| Sun Pharmaceutical Industries Inc. | 2 | $43 |
| Novartis | 2 | $38 |
| Rayner Intraocular Lenses Limited | 1 | $27 |
| Ocular Therapeutix, Inc. | 1 | $23 |
| Merz Pharmaceuticals, LLC | 1 | $19 |
| Sight Sciences, Inc. | 1 | $19 |
| Shire North American Group Inc | 1 | $16 |
| Vantage Technology LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CIRRUS HD-OCT$4,150
How this compares
$6,203 in reported general payments places this provider in the 75th percentile of 588 ophthalmology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 80 | $88,657 |
| RocklatanNetarsudil Mesylat/Latanoprost | 73 | $49,207 |
| LumiganBimatoprost | 74 | $31,364 |
| ProlensaBromfenac Sodium | 81 | $28,295 |
| Lotemax SmLoteprednol Etabonate | 94 | $23,603 |
| Latanoprost | 1,705 | $22,000 |
| CombiganBrimonidine Tartrate/Timolol | 39 | $16,887 |
| Prednisolone Acetate | 372 | $16,431 |
| Alphagan PBrimonidine Tartrate | 21 | $11,322 |
| MoxifloxacinMoxifloxacin Hcl | 403 | $8,994 |
| VyzultaLatanoprostene Bunod | 15 | $8,264 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 47 | $6,640 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 427 | $5,841 |
| Brimonidine Tartrate | 377 | $5,073 |
| Timolol Maleate | 417 | $5,006 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $151 | $148,230214 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Lotemax Sm | $382 | $51,898175 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $114 | $49,20773 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $166 | $8,26415 claims |
| AlconSimbrinza | $353 | $3,74118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 588 ophthalmology providers in North Carolina.
Other ophthalmology in Wilson
- Sharon FekratWilson$142K
- Glenn JaffeDurham$38.5M
- Lejla VajzovicDurham$7.5M
- Andrew AntoszykCharlotte$4M
- Majda HadziahmetovicDurham$2.4M
- Preeya GuptaRaleigh$2M
- Thomas WilliamsHickory$1.8M
- James HarrisHickory$1.4M
- Rajiv ShahWinston Salem$1.3M
- Patrick KeltyHickory$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.